No Data
Signed a collaborative research agreement with the National Center of Neurology and Psychiatry, initiating apolipoprotein E genetic testing in the AD DMT Registry.
On November 26, 2024, Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, hereinafter referred to as Eisai) and Biogen Japan Co., Ltd. (Headquarters: Tokyo, President: Yukisuke Tsutae, hereinafter referred to as Biogen Japan) have recently announced that Eisai has partnered with the National Center of Neurology and Psychiatry (NCNP) in Tokyo, an independent administrative institution engaged in mental and neurological healthcare research, to collaborate on various projects within NCNP as the leading research institution.
Idemitsu Kosan, Sumitomo Osaka Cement, etc. (additional) Rating
Upgraded - bullish code stock name brokerage firm previous changed after----------------------------------------------------------<9468>KADOKAWA Macquarie "Neutral" "Outperform" <5233> Taiheiyo Cement Daiwa "2" "1" target stock price change code stock name brokerage firm previous changed after----------------------------------------------
Rosevaramin Injectable 25mg for Amyotrophic Lateral Sclerosis (ALS) newly released in japan
Eisai Co., Ltd. (Headquarters: Tokyo, Representative Executive Officer/CEO: Haruo Naito) announced today the release of the drug "Rozeparamin Muscle Injection 25mg" (generic name: Mecobalamin) for amyotrophic lateral sclerosis (ALS) in Japan to "suppression of functional impairment progression in ALS". This drug obtained manufacturing and marketing approval on September 24, 2024, and today it is listed for premium listing. The approval of this drug was from national universities.
Anticancer drug "Tasfigo tablet 35mg" (generic name: Tasulugratinib hydrochloride)
On November 20, 2024, Eisai Co., Ltd. (Headquarters: Tokyo, Representative Executive Officer CEO: Haruo Naito) announced today the new launch in Japan of the selective tyrosine kinase inhibitor "Tasfigo Tablets 35mg" (generic name: Taslugratinib Dihydrochloride) for the indication of "unresectable cholangiocarcinoma positive for FGFR2 fusion gene that has worsened after cancer chemotherapy." This drug was approved on September 24, 2024.
The Nikkei average fell significantly, weighed down by the decline in tech stocks.
Last weekend, the Dow Jones Industrial Average in the USA market closed with a loss of 305.87 points at 43444.99 points, while the NASDAQ closed with a loss of 427.53 points at 18680.12 points. The selling pressure continued following hawkish remarks by Federal Reserve Chair Powell, leading to a decline after the opening. Buying interest, which was driven by expectations of policies supporting corporate performance such as deregulation by the upcoming Trump administration, paused. Furthermore, the speculation of an additional rate cut in December receded after comments from Fed officials, contributing to the continued decline. US stocks that declined.
JP Movers | M3 Rose 5.64%, Leading Nikkei 225 Components, Disco Topped Turnover List
Market sentiment was stable today as Nikkei 225 components continued to trade sideways, with M3(2413.JP) being the top gainer today, rising 5.64% to close at 1320.0 yen. In addition, the top loser was Dentsu Group(4324.JP)，falling 10.01% to end at 3687.0 yen.
No Data
No Data
